Home › Funds › Defilade Capital Management, L.P. › DNLI

Defilade Capital Management, L.P. position in DNLI

DENALI THERAPEUTICS INC · Health Care

Defilade Capital Management, L.P. reported holding 391,866 shares of DNLI (DENALI THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$10.1M, representing 1.35% of its reported portfolio and ranking #32 among its reported holdings. Defilade Capital Management, L.P. has disclosed DNLI holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

Latest position (Q2 2026)391.87K sh
Reported value held$10.08M
Portfolio Weight1.35%
First reportedQ4 2025
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Defilade Capital Management, L.P.'s DNLI position evolved

Defilade Capital Management, L.P. first disclosed a stake in DNLI in Q4 2025 at 656,713 shares (US$10.8M). The position peaked in Q1 2026 at 1,359,969 shares, worth US$26.1M. Across 3 filings, Defilade Capital Management, L.P. increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 391,866 shares valued at US$10.1M — a reduction of -968,103 shares quarter over quarter.. Notable position changes include a 107% increase in Q1 2026 (shares rose 34% over the following quarter), a 71% trim in Q2 2026 (shares fell 20% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2025 656.71K $10.84M New
Q1 2026 1.36M $26.11M Add
Q2 2026 391.87K $10.08M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About DNLI and 13F data

DNLI (DENALI THERAPEUTICS INC) is a Health Care company. 45 other funds we track also report a position in DNLI — the largest reported positions include Temasek Holdings (US$180.4M), Temasek Holdings (Private) Ltd (US$180.4M), BAKER BROS. ADVISORS LP (US$96.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding DNLI

All DNLI fund holders →

FAQ

How long has Defilade Capital Management, L.P. held DNLI?

Defilade Capital Management, L.P. has disclosed DNLI holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

What is Defilade Capital Management, L.P.'s current position in DNLI?

As of Q2 2026, Defilade Capital Management, L.P. holds 391.87K shares of DNLI (DENALI THERAPEUTICS INC), valued at $10.08M, representing 1.35% of its reported portfolio and ranking #32.

Has Defilade Capital Management, L.P. been buying or selling DNLI?

In the latest 13F filing (Q2 2026), Defilade Capital Management, L.P. reduced its position in DNLI. The position peaked in Q1 2026 at 1.36M shares.

Which other funds hold DNLI?

Other major institutional holders of DNLI include Temasek Holdings, Temasek Holdings (Private) Ltd, BAKER BROS. ADVISORS LP, among 45 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.